Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276223 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 722
- Enrollment target
NCT01276223 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 722 participants.
The verdict
NCT01276223, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 722 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.
Interventions
- DRUG Difluprednate 0.05% ophthalmic emulsion
- OTHER Difluprednate vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 722 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01276223
The ClinicalTrials.gov registry entry for NCT01276223 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 722 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Difluprednate 0.05% ophthalmic emulsion is the first listed.
NCT01276223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01276223 about?
NCT01276223 is a clinical study titled "Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients". The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.
What is the current status of trial NCT01276223?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 722 participants. The study started on 2011-02. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01276223?
The interventions under investigation include: Difluprednate 0.05% ophthalmic emulsion (DRUG), Difluprednate vehicle (OTHER).
Who is sponsoring clinical trial NCT01276223?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.